Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

USPSTF Recommendation Updates for Women With BRCA-Related Cancer
Quality Care 2019: Impact of Breast Cancer on Key Support Person’s Employment
Is Red Meat Consumption Linked to Breast Cancer Risk?
Two-Drug Combination Targets Resistance in Cancer
FDA Draft Guidance Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
Comparing First-Line Treatments in Triple-Negative Breast Cancer
Real-World Data on Palbociclib Plus Endocrine Therapy in Men With Advanced Breast Cancer
IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer
Is Soy Intake Related to Bone Fractures for Breast Cancer Survivors?
FDA Requests Manufacturer Recall of Certain Textured Breast Implants
Does Eribulin Mesylate Plus Pembrolizumab Improve Outcomes in Metastatic Breast Cancer?
Communicating With Older Patients About the Need for Breast Cancer Screening
Updated ASCO Clinical Practice Guideline Integrates TAILORx Trial Results in Breast Cancer
NALA Trial: Neratinib Versus Lapatinib Combination Therapy for Metastatic Breast Cancer
De-escalation of Bone-Targeting Agents for Bone Metastases From Breast Cancer
SOPHIA Trial: Adding Margetuximab or Trastuzumab to Chemotherapy in Breast Cancer
Comparing Radiation Regimens in Early-Stage Breast Cancer
Does Environmental Quality Impact the Odds of Developing Aggressive Breast Cancer?
Racial Differences in Risk of Aggressive Breast Cancer After Ductal Carcinoma in Situ
ASCO 2019: Novel Targeted Therapy Active in Metastatic Breast Cancer
ASCO 2019: Final Results of KRISTINE Trial of Neoadjuvant Regimens in HER2-Positive Breast Cancer
New Trastuzumab Biosimilar Approved by the FDA
ASCO 2019: Can Clinical Risk Stratification Predict Chemotherapy Benefit in Early Breast Cancer?
Targeting Mitochondrial Metabolism in Triple-Negative Breast Cancer
ACP Issues New Guidance Statement for Breast Cancer Screening in Average-Risk Women
ASCO 2019: CDK4/6 Inhibitor Plus Endocrine Therapy Improves Overall Survival in Advanced Breast Cancer
Retrospective Update on Nipple-Sparing Mastectomy
U.S. and Canadian Home Recovery Programs After Mastectomy
FDA Approves Alpelisib Combination Therapy for Advanced Breast Cancer
Breast Cancer Treatment Outcomes in Young Women
Effect of Chemotherapy Scheduling on Quality of Life in Advanced Breast Cancer
ARRS 2019: BI-RADS 3 Lesions Identified on High-Risk Screening Breast MRI
ASCO 2019: Can a Low-Fat Diet Reduce Breast Cancer Mortality?
Leronlimab Granted Fast Track Designation in Metastatic Triple-Negative Breast Cancer
ESMO Breast 2019: Global Survey of HER2 Testing Shows Room for Improvement
ESMO Breast 2019: Intermittent vs. Continuous Chemotherapy in HER2-Negative Breast Cancer
ASBrS 2019: Some Women With HER2-Positive Breast Cancer May Not Need Surgery
Ado-Trastuzumab Emtansine Granted FDA Approval in HER2-Positive Early Breast Cancer
ESMO Breast 2019: De-escalation Strategy for Women With HER2-Positive Metastatic Breast Cancer
ESTRO 2019: 10-Year Follow-up of Whole-Breast Irradiation in Low-Risk Breast Cancer
Breast Cancer’s Genetic Relationship to Other Cancers
Brain Metastases and Estrogen: Is There a Link in Triple-Negative Breast Cancer?
Canada Halts Sales of Cancer-Linked Breast Implants
INT230-6 Granted Fast Track Designation in Metastatic Triple-Negative Breast Cancer
AACR 2019: Primary Tumor Surgery for Advanced HER2-Positive Breast Cancer
AACR 2019: Predicting Breast Cancer Survival With Estrogen Byproducts
HOPA 2019: Does Receptor Expression Affect Efficacy of Talazoparib in Advanced Breast Cancer?
Is There a Link Between Age Acceleration and Breast Cancer Risk?
FDA Extends Indication of Palbociclib Combination to Men With Breast Cancer
Novel Antibody Drug-Conjugate in Metastatic Triple-Negative Breast Cancer
Study Finds Shifting Trend in Breast Cancer Risk in Asian American Women


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.